Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)

Peer Review reports

Original Submission
13 Jul 2020	Submitted	Original manuscript
29 Jul 2020	Reviewed	Reviewer Report - NIKOLAOS GRIVAS
27 Aug 2020	Reviewed	Reviewer Report - Petros Grivas
9 Oct 2020	Author responded	Author comments - Andrea Necchi
Resubmission - Version 2
9 Oct 2020	Submitted	Manuscript version 2
20 Oct 2020	Author responded	Author comments - Andrea Necchi
Resubmission - Version 3
20 Oct 2020	Submitted	Manuscript version 3
Publishing
26 Oct 2020	Editorially accepted
7 Nov 2020	Article published	10.1186/s12894-020-00752-w

Back to article page